Literature DB >> 10083278

Prolonged survival of islet allografts following combined therapy with tacrolimus and leflunomide.

C Rastellini1, L Cicalese, R Leach, M Braun, J J Fung, T E Starzl, A S Rao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10083278      PMCID： PMC2976499          DOI： 10.1016/s0041-1345(98)01598-x

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  4 in total

Review 1.  Adverse effects associated with the use of FK 506.

Authors:  J J Fung; M Alessiani; K Abu-Elmagd; S Todo; R Shapiro; A Tzakis; D Van Thiel; J Armitage; A Jain; J McCauley
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

2.  Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent.

Authors:  C C Küchle; G H Thoenes; K H Langer; H U Schorlemmer; R R Bartlett; R Schleyerbach
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

3.  In vivo effects of leflunomide on normal pancreatic islet and syngeneic islet graft function.

Authors:  Z Guo; A S Chong; J Shen; P Foster; H N Sankary; L McChesney; D Mital; S C Jensik; H Gebel; J W Williams
Journal:  Transplantation       Date:  1997-03-15       Impact factor: 4.939

4.  Diabetes mellitus after renal transplantation in the cyclosporine era--an analysis of risk factors.

Authors:  N B Sumrani; V Delaney; Z K Ding; R Davis; P Daskalakis; E A Friedman; K M Butt; J H Hong
Journal:  Transplantation       Date:  1991-02       Impact factor: 4.939
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.